News Axsome bounces back as FDA clears depression drug Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was
News Axsome faces delay for depression drug, hitting shares hard The FDA was supposed to be delivering its verdict on Axsome Therapeutics' depression therapy AXS-05 in less than a fortnight – but instead has delivered the company a letter outlining defic
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face